Home › Funds › Aldebaran Capital, LLC › AMLX
Aldebaran Capital, LLC position in AMLX
AMYLYX PHARMACEUTICALS INC · Health Care
Aldebaran Capital, LLC reported holding 196,032 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$5.7M, representing 4.10% of its reported portfolio and ranking #7 among its reported holdings. Aldebaran Capital, LLC has disclosed AMLX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Aldebaran Capital, LLC's AMLX position evolved
Aldebaran Capital, LLC first disclosed a stake in AMLX in Q2 2024 at 269,803 shares (US$513K). The position peaked in Q3 2026 at 196,032 shares, worth US$5.7M. Across 10 filings, Aldebaran Capital, LLC increased the stake 0 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 196,032 shares valued at US$5.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 269.80K | $512.63K | New |
| Q3 2024 | 269.80K | $874.16K | Hold |
| Q4 2024 | 262.75K | $993.21K | Reduce |
| Q1 2025 | 259.25K | $917.76K | Reduce |
| Q2 2025 | 217.83K | $1.40M | Reduce |
| Q3 2025 | 204.47K | $2.78M | Reduce |
| Q4 2025 | 198.51K | $2.40M | Reduce |
| Q1 2026 | 197.89K | $2.75M | Hold |
| Q2 2026 | 195.89K | $3.52M | Reduce |
| Q3 2026 | 196.03K | $5.70M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AMLX and 13F data
AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in AMLX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$149.7M), TCG Crossover Management, LLC (US$112.1M), Commodore Capital LP (US$101.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AMLX
- PERCEPTIVE ADVISORS LLC 8.33M sh · $149.69M · Q2 2026
- TCG Crossover Management, LLC 6.24M sh · $112.14M · Q2 2026
- Commodore Capital LP 5.65M sh · $101.47M · Q2 2026
- Saturn V Capital Management LP 4.62M sh · $83.05M · Q2 2026
- Siren, L.L.C. 2.48M sh · $72.19M · Q3 2026
- First Light Asset Management, LLC 3.02M sh · $54.30M · Q2 2026
- Almitas Capital LLC 974.88K sh · $17.51M · Q2 2026
- Boxer Capital Management, LLC 800.00K sh · $14.37M · Q2 2026
- GREAT POINT PARTNERS LLC 700.00K sh · $12.57M · Q2 2026
- Parkman Healthcare Partners LLC 398.78K sh · $7.16M · Q2 2026
- STEMPOINT CAPITAL LP 384.30K sh · $6.90M · Q2 2026
More on Aldebaran Capital, LLC
FAQ
How long has Aldebaran Capital, LLC held AMLX?
Aldebaran Capital, LLC has disclosed AMLX holdings in 10 of the last 10 reported quarters, going back to Q2 2024.
What is Aldebaran Capital, LLC's current position in AMLX?
As of Q3 2026, Aldebaran Capital, LLC holds 196.03K shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $5.70M, representing 4.10% of its reported portfolio and ranking #7.
Has Aldebaran Capital, LLC been buying or selling AMLX?
In the latest 13F filing (Q3 2026), Aldebaran Capital, LLC held unchanged its position in AMLX. The position peaked in Q3 2026 at 196.03K shares.
Which other funds hold AMLX?
Other major institutional holders of AMLX include PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, Commodore Capital LP, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.